| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3293316 | Gastroenterology | 2012 | 13 Pages |
Abstract
Administration of 800 mg rifaximin-EIR twice daily for 12 weeks induced remission with few adverse events in patients with moderately active CD.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Cosimo Prantera, Herbert Lochs, Maria Grimaldi, Silvio Danese, Maria Lia Scribano, Paolo Gionchetti, Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease) Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease),